Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, is fully committed to supporting the national effort against COVID-19 with all available resources. Since the start of the crisis, Quirónsalud has worked in close and trustful cooperation with national and regional healthcare authorities to provide the best possible treatment to the greatest possible number of patients.

Quirónsalud’s network currently comprises about 400 ICU beds for adults in almost 50 hospitals across Spain. The company is undertaking significant efforts to further increase this number in the short term, while continuing to treat other patients who urgently need medical support such as for chemotherapy, giving birth, and other emergencies.

Despite the high number of suspected and confirmed COVID-19 cases entering Quirónsalud’s hospitals, the company has kept every hospital fully operational. This is to a large extent due to the outstanding commitment of Quirónsalud’s medical and nursing staff, who deserve the utmost recognition and gratitude. So far, Quirónsalud has also been able to secure sufficient quantities of medical materials for all its hospitals, despite rapidly rising demand for critical supplies.

In the course of the formal declaration of a ‘State of Alarm’, the Spanish government has temporarily obtained the right to direct all hospitals in the country, allowing the healthcare authorities to leverage all available resources to treat COVID-19 patients as effectively as possible. Such an option is embedded in the established crisis management plans of many other European countries as well. Quirónsalud fully supports this measure, as it allows centralized capacity management, and hence rapid responses to changing circumstances and a full dedication of the entire system to fight the coronavirus.

Rumors about a “nationalization” of Spain’s private hospital system are clearly wrong and without any basis. Quirónsalud continues to manage its hospitals, and is already operating the additional beds requested by the authorities, in the joint effort against the COVID-19 threat for the benefit of Spain and the broader society.

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Clínica de la Mujer in Bogotá, further expanding the company’s presence in Colombia’s attractive private hospital market. Following the acquisitions in Medellin and Cali in the two previous years, this is the company’s first acquisition in Colombia’s capital city.

Clínica de la Mujer is located in a prime residential area of Bogotá, Colombia’s largest city, with a population of 7.4 million. The hospital puts a special focus on gynecology, pediatrics and obstetrics, helping mothers to deliver about 3,000 babies annually, while also offering a broad range of other medical specialties and services. It has approximately 80 beds and five operating rooms, and generated sales of about €20 million in 2019.

Both parties have agreed not to disclose the terms of the acquisition. The transaction is expected to close in the second quarter of 2020, pending antitrust clearance. Fresenius expects the acquisition of Clínica de la Mujer to be accretive to Group net income  in fiscal year 2020.

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Clínica de la Mujer in Bogotá, further expanding the company’s presence in Colombia’s attractive private hospital market. Following the acquisitions in Medellin and Cali in the two previous years, this is the company’s first acquisition in Colombia’s capital city.

Clínica de la Mujer is located in a prime residential area of Bogotá, Colombia’s largest city, with a population of 7.4 million. The hospital puts a special focus on gynecology, pediatrics and obstetrics, helping mothers to deliver about 3,000 babies annually, while also offering a broad range of other medical specialties and services. It has approximately 80 beds and five operating rooms, and generated sales of about €20 million in 2019.

Both parties have agreed not to disclose the terms of the acquisition. The transaction is expected to close in the second quarter of 2020, pending antitrust clearance. Fresenius expects the acquisition of Clínica de la Mujer to be accretive to Group net income in fiscal year 2020.

Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company’s presence in Colombia’s attractive private hospital market.

CMI is located in a central district of Cali, the biggest city in southwestern Colombia with a population of 2.4 million. As one of the most prestigious private hospitals in Latin America, repeatedly recognized for its medical quality as well as its state-of-the-art infrastructure and medical technology, CMI offers a comprehensive range of medical specialties and services. The hospital has about 350 beds, 17 operating rooms and 250 consultation rooms, and generated sales of about €130 million in 2018. The total consideration amounts to approximately €300 million.

The purchase of CMI is another important step in strengthening Quirónsalud’s presence in Colombia’s growing and consolidating healthcare services market. With this acquisition, Quirónsalud becomes one of the leading private hospital operators in the country. The transaction is expected to close in the first quarter of 2020, pending anti-trust clearance. Fresenius expects CMI to be accretive to Group net income¹ in fiscal year 2020.

¹Net income attributable to shareholders of Fresenius SE & Co. KGaA

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company’s presence in Colombia’s attractive private hospital market.

CMI is located in a central district of Cali, the biggest city in southwestern Colombia with a population of 2.4 million. As one of the most prestigious private hospitals in Latin America, repeatedly recognized for its medical quality as well as its state-of-the-art infrastructure and medical technology, CMI offers a comprehensive range of medical specialties and services. The hospital has about 350 beds, 17 operating rooms and 250 consultation rooms, and generated sales of about €130 million in 2018. The total consideration amounts to approximately €300 million.

The purchase of CMI is another important step in strengthening Quirónsalud’s presence in Colombia’s growing and consolidating healthcare services market. With this acquisition, Quirónsalud becomes one of the leading private hospital operators in the country. The transaction is expected to close in the first quarter of 2020, pending anti-trust clearance. Fresenius expects CMI to be accretive to Group net income* in fiscal year 2020.

*Net income attributable to shareholders of Fresenius SE & Co. KGaA

Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

Quirónsalud, Spain’s largest private hospital group and part of Fresenius Helios, has acquired CediMed, a leading medical diagnostics group in Colombia. CediMed operates seven centrally located centers in Medellin, a major city of 2.5 million people. The company offers a comprehensive range of state-of-the-art diagnostic imaging and laboratory services. The total investment is about €40 million.

Following Quirónsalud's entry into Colombia in 2019, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating healthcare services markets. Fresenius Helios expects the transaction to close in the next few months, pending antitrust clearance.